

SAS/AC/:kam 09/30/03 223377
PATENT

Attorney Reference Number 4239-58378
Application Number 09/807,148

Remarks

Claims 9-11 are canceled herein solely for the advancement of prosecution and not for matters pertaining to patentability. New claims 80 and 81 are added herein. Support for new claims 80 and 81 can be found in the specification at page 25, line 40 through page 28, line 3.

The specification is amended to insert the priority claim, which is shown on the attached copy of the Filing Receipt.

No new matter is added by any of the foregoing amendments. Examination of the subject application is respectfully requested.

Telephone Interview

Applicants thank Examiner Yu for the helpful telephone conference on September 29, 2003 with Applicants' representative, Susan Alpert Siegel, Ph.D. Matters pertaining to the restriction requirement were discussed. In particular, the rejoining of claims directed to methods of inhibiting endothelial cell growth and methods of inhibiting angiogenesis *in vivo* was discussed. In response to the request to elect a single disease process, claims 9-11 are canceled herein, and claims 80-81, directed to the treatment of tumors, are added.

SAS/AC/:kam 09/30/03 223377
PATENT

Attorney Reference Number 4239-58378
Application Number 09/807,148


Conclusion

If any minor matters remain to be addressed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446